Table 2 Odds ratios and corresponding 95% confidence intervals for personal history factors as predictors of BRCA1 and BRCA2 pathogenic variant carrier status

From: Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort

 BRCA1BRCA2
PhenotypeCaucasianAfrican AmericanAsianHispanicCaucasianAfrican AmericanAsianHispanic
DCIS1.0 (0.7, 1.3)0.2 (0.0, 1.2)0.8 (0.2, 2.6)0.6 (0.2, 2.0)1.3 (1.1, 1.6)0.9 (0.4, 1.9)0.5 (0.2, 1.2)1.6 (0.9, 3.1)
TN + dx <5015.9 (13.4, 18.9)15.7 (9.8, 25.2)23.5 (10.9, 50.6)25.9 (15.7, 42.8)3.1 (2.3, 4.0)3.4 (1.9, 5.9)1.5 (0.5, 4.3)2.1 (0.9, 4.9)
TN + dx ≥505.1 (4.2, 6.3)2.8 (1.4, 5.4)9.0 (3.1, 26.6)4.6 (2.2, 10.0)2.9 (2.3, 3.7)1.5 (0.7, 2.9)1.9 (0.7, 5.6)0.9 (0.3, 3.0)
TN – dx <501.7 (1.4, 2.1)2.5 (1.5, 4.2)3.1 (1.5, 6.1)2.9 (1.7, 4.9)2.5 (2.1, 2.9)2.4 (1.5, 3.9)1.0 (0.6, 1.8)2.0 (1.2, 3.3)
TN – dx ≥500.5 (0.4, 0.7)0.5 (0.2,1.5)1.3 (0.5, 3.6)0.7 (0.2, 2.0)1.5 (1.2, 1.7)1.4 (0.8, 2.5)0.9 (0.4, 1.8)1.8 (1.0, 3.2)
TN . dx <503.8 (3.2, 4.5)5.4 (3.3, 9.0)4.2 (1.9, 9.1)4.8 (2.9, 8.1)2.4 (2.0, 2.8)3.2 (1.9, 5.2)0.9 (0.4, 1.9)1.8 (1.0, 3.2)
TN . dx ≥501.1 (0.9, 1.4)1.2 (0.5, 3.1)2.0 (0.6, 6.0)1.4 (1.2, 1.8)1.4 (0.7, 2.8)1.2 (0.5, 2.9)1.2 (0.5,2.9)
Bilateral BC1.6 (1.3, 1.9)1.8 (1.2, 2.8)1.7 (0.8, 3.4)2.2 (1.2, 3.9)1.2 (1.0, 1.5)2.0 (1.4, 3.1)0.8 (0.3, 1.9)1.1 (0.5, 2.2)
OV <6010.7 (9.2, 12.4)8.6 (4.7, 15.7)17.2 (8.7, 34.0)17.5 (10.6, 28.8)4.0 (3.3, 4.8)3.0 (1.5, 6.2)1.4 (0.6, 3.3)3.9 (2.1, 7.1)
OV ≥604.2 (3.4, 5.2)1.1 (0.1, 7.9)12.0 (4.9, 29.2)14.1 (7.3, 27.4)4.9 (4.1, 5.8)4.3 (2.0, 9.4)4.7 (2.2, 10.0)2.6 (1.0, 6.8)
Pancreatic1.3 (0.8, 2.3)2.3 (0.5, 10.3)3.9 (3.0, 5.2)2.4 (0.8, 7.3)5.1 (1.8, 14.7)6.3 (2.4, 17.0)
Male BC1.1 (0.4, 3.1)6.3 (4.6, 8.6)4.0 (1.6, 10.2)1.8 (0.2, 15.6)5.6 (1.2, 26.1)
Pr Ca<601.1 (0.3, 4.3)1.4 (0.6, 3.2)3.2 (0.4, 27.1)10.3 (1.2, 87.6)
Pr Ca≥601.9 (0.7, 5.1)2.4 (1.4, 4.1)9.7 (1.8, 51.4)5.1 (0.5, 58.9)16.3 (3.2, 83.8)
  1. BC breast cancer, DCIS ductal carcinoma in situ, TN triple negative.